

Contains Nonbinding Recommendations
Draft Guidance on Vortioxetine Hydrobromide

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Vortioxetine hydrobromide

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover in vivo
Strength: Eq 20 mg base
Subjects: Normal, healthy males and nonpregnant females, general population

2. Type of study: Fed
Design: Single-dose, two-way crossover in vivo
Strength: Eq 20 mg base
Subjects: Normal, healthy males and nonpregnant females, general population

Analytes to measure (in appropriate biological fluid): Vortioxetine in plasma

Bioequivalence based on (90% CI): Vortioxetine

Waiver request of in vivo testing: Eq 5 mg base, eq 10 mg base, and eq 15 mg base strengths based on (i) acceptable bioequivalence studies on the eq 20 mg base strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods Web site, available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. The dissolution information for this product is available at this website. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.